This week, the White House announced a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1 weight loss ...

A rare intracranial brain-recording study revealed that tirzepatide, a GLP-1 and GIP receptor agonist, temporarily silences craving-related neural activity in a key reward circuit of the brain.

A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as ...

This article was reviewed by Darragh O’Carroll, MD. Diabetes Medications for Weight Loss: What to Know Key takeaways: Some ...

Elevated autoantibodies against incretin hormones may indicate poorer outcomes in diabetes, highlighting potential for new ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes medications — also known as GLP-1 and GIP injections — are changing the way we ...

Tirzepatide is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. Both GIP and GLP-1 receptors are found in areas of the human brain ...

This article was reviewed by Darragh O’Carroll, MD. GLP-1 for Weight Loss: Everything You Need to Know Key takeaways: GLP-1s ...

BERLIN — A novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist combined into a single drug (LY3298176, Lilly), dubbed a "twincretin," ...

A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as ...